AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 4045435
Drug: plasma-derived hepatitis
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: plasma-derived hepatitis B vaccine (5-micrograms)
Trial: 4045435
Drug: plasma-derived hepatitis
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: plasma-derived hepatitis B vaccine (10-micrograms)
Trial: 2956867
Drug: Intravenous enoximone
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous enoximone at a maximum cumulative dose of 3.0 mg/kg
Trial: 2956867
Drug: Intravenous enoximone
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous enoximone at a maximum cumulative dose of 10.5 mg/kg
Trial: 2956867
Drug: Intravenous enoximone
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous enoximone
Trial: 2956867
Drug: Adverse effects
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse effects of intravenous enoximone
Trial: 25427521
Drug: Individualized homeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized homeopathic treatment
Trial: 23174090
Drug: D-cycloserine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine (1000 mg/d)
Trial: 16649875
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of abstinence-based vouchers and cognitive-behavioral therapy
Trial: 10819856
Drug: Atosiban (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atosiban (30 microg/min continuous subcutaneous infusion)
Trial: 6437467
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg SSHA
Trial: 6437467
Drug: 37.5 mg
RxNorm normalized name: pemoline 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5 mg SSHA
Trial: 6437467
Drug: 5000 units
RxNorm normalized name: A-25, 25000 units oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 units sodium heparin
Trial: 30178515
Drug: Genotype-guided tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Genotype-guided tacrolimus dosing
Trial: 30178515
Drug: Standard tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard tacrolimus dosing
Trial: 27553581
Drug: Landiolol infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Landiolol infusion (5 μg/kg/min during general anesthesia)
Trial: 19921354
Drug: Landiolol infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Landiolol infusion
Trial: 24554512
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pill (OC) containing ethynyloestradiol and cyproterone acetate (EE‐CPA) for 4 months
Trial: 24554512
Drug: Metformin (MET)
RxNorm normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (MET) 850 mg bid for 4 months
Trial: 24554512
Drug: Metformin (MET)
RxNorm normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (MET) or EE‐CPA for 4 months
Trial: 15321222
Drug: 1 L
RxNorm normalized name: BLUE 1 LAKE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L Ringer's solution preload administered over 10 min before spinal anaesthesia
Trial: 15321222
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received prophylactic infusion of ephedrine (60 mg in Ringer's solution 1000 ml) after spinal anaesthesia
Trial: 7923256
Drug: 2 mg/day
RxNorm normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/day terazosin
Trial: 7923256
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day terazosin
Trial: 7923256
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day terazosin
Trial: 3136963
Drug: Indomethacin 25
RxNorm normalized name: indomethacin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 25 mg three times daily for the first six postoperative weeks
Trial: 25227499
Drug: Bevacizumab 1.25
RxNorm normalized name: Bevacizumab 1.25mg/0.05mL Intraocular solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 1.25 mg
Trial: 26445075
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment regimen
Trial: 26445075
Drug: Discontinuous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuous treatment regimen
Trial: 22464973
Drug: JNJ-37822681 10
RxNorm normalized name: JNJ-37822681
DrugBank: JNJ-37822681 (DB12579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-37822681 10 mg bid
Trial: 22464973
Drug: JNJ-37822681 20
RxNorm normalized name: JNJ-37822681
DrugBank: JNJ-37822681 (DB12579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-37822681 20 mg bid
Trial: 22464973
Drug: JNJ-37822681 30
RxNorm normalized name: JNJ-37822681
DrugBank: JNJ-37822681 (DB12579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-37822681 30 mg bid
Trial: 21296118
Drug: 9-valent pneumococcal
RxNorm normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent pneumococcal and meningococcal serogroup C conjugate vaccine (9vPnC‐MnCC)
Trial: 21296118
Drug: 9-valent pneumococcal
RxNorm normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent pneumococcal conjugate vaccine (9vPnC)
Trial: 19293355
Drug: Beraprost sodium,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beraprost sodium, 120 microg daily for 8 weeks
Trial: 15153174
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg lansoprazole orally disintegrating tablet dispersed in water and administered orally via syringe
Trial: 15153174
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg intact lansoprazole orally disintegrating tablet administered directly onto the tongue without water
Trial: 11557646
Drug: leflunomide 20
RxNorm normalized name: leflunomide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: leflunomide 20 mg/day
Trial: 11557646
Drug: sulfasalazine 2
RxNorm normalized name: SULFASALAZINE 250MG/5ML SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulfasalazine 2 g/day
Trial: 7835329
Drug: Breakfast cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breakfast cereal with 43 g sucrose
Trial: 7835329
Drug: Breakfast cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breakfast cereal with 0 g sucrose (non-sweetened)
Trial: 29797909
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at Feishu (BL 13), Xinshu (BL 15), Pishu (BL 20), Ganshu (BL 18), Shenshu (BL 23), Geshu (BL 17), and Shenmen (HT 7) once a day, with a 2-day interval after every 5 days of treatment for 3 weeks.
Trial: 29797909
Drug: Alprazolam (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.4 mg or 0.8 mg) orally before sleep for 3 weeks.
Trial: 23506383
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test, HbA1c, biochemical and anthropometric data
Trial: 21685640
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality Based Exposure Therapy (VRBET)
Trial: 21685640
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality Based Exposure Therapy (VRBET) combined with cognitive therapy
Trial: 15612966
Drug: Budesonide once
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide once daily (up to 800 microg per day)
Trial: 15612966
Drug: Budesonide twice
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide twice daily (up to 800 microg per day)
Trial: 7717370
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose 13‐Cis‐Retinoic Acid (80 mg daily for 6 months)
Trial: 7717370
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose 13‐Cis‐Retinoic Acid (200 mg po daily for 3 months)
Trial: 7717370
Drug: Danazol (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (800 mg po daily for 3 months)
Trial: 2235346
Drug: L-cysteine (L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-cysteine (L group)
Trial: 631413
Drug: Chlormethiazole syrup
RxNorm normalized name: chlormethiazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormethiazole syrup
Trial: 31869281
Drug: Individually randomized
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individually randomized group treatment trial
Trial: 26482865
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (2 × 500 mg/day) and E (400 IU/day)
Trial: 28991404
Drug: Inactivated trivalent
RxNorm normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated trivalent influenza vaccine (TIV)
Trial: 22180452
Drug: Prednisone 25
RxNorm normalized name: prednisone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 25 mg
Trial: 3871188
Drug: Prednisone 60
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 60 mg
Trial: 22180452
Drug: Prednisone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (all doses)
Trial: 19566585
Drug: SLIT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLIT with a glycerinated mixture of birch, hazel and alder with a cumulative weekly dose of 24,000 SQ-U
Trial: 19566585
Drug: SLIT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLIT with a glycerinated mixture of birch, hazel and alder with a cumulative weekly dose of 200,000 SQ-U
Trial: 16253583
Drug: Both atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both atorvastatin and pravastatin
Trial: 10572352
Drug: Fluoxetine for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine for six months
Trial: 8951782
Drug: Aggressive cytoreductive
RxNorm normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive cytoreductive treatments with chemotherapeutic agents
Trial: 8951782
Drug: Phlebotomy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phlebotomy and preventive antiplatelet therapy
Trial: 1829574
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of alteplase (70 mg or 80 mg if body weight >= 90 kg)
Trial: 6667627
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg slow-release salbutamol tablet
Trial: 6667627
Drug: 1 standard
RxNorm normalized name: Kroger Universal 1 Standard Lancet 21G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 standard 4 mg tablet
Trial: 6667627
Drug: 2 standard
RxNorm normalized name: Onguard2 Standard 20 mm Vial Adaptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 standard 4 mg tablets
Trial: 31752952
Drug: Inspiratory flow
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory flow of 400, 800, and 1200 ml/s
Trial: 16940738
Drug: Intramuscular syntometrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular syntometrine
Trial: 19603316
Drug: Intravenous syntocinon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous syntocinon
Trial: 15041401
Drug: EC-MPS, 720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC-MPS, 720 mg b.i.d.
Trial: 15041401
Drug: MMF, 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF, 1000 mg b.i.d.
Trial: 11583477
Drug: Thalidomide at
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide at a dose of 200 mg daily for 4 weeks
Trial: 10933340
Drug: Flunitrazepam (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (2, 4 and 8 mg/70 kg)
Trial: 10933340
Drug: Triazolam (0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.25, 0.5 and 1 mg/70 kg)
Trial: 10933340
Drug: Flunitrazepam (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (highest dose)
Trial: 10933340
Drug: Triazolam (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (all doses)
Trial: 674351
Drug: Imipramine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (100 mg orally)
Trial: 674351
Drug: Lofepramine (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lofepramine (140 mg orally)
Trial: 31279028
Drug: Crisaborole 2%
RxNorm normalized name: CRISABOROLE 2% OINT,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crisaborole 2% ointment
Trial: 26082611
Drug: Amlodipine orotate/olmesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine orotate/olmesartan medoxomil 10/40 mg
Trial: 26082611
Drug: Amlodipine besylate/olmesartan
RxNorm normalized name: Amlodipine Besylate/Olmesartan Medoxomil 5 MG-20 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate/olmesartan medoxomil 10/40 mg
Trial: 19694343
Drug: Symbiotic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbiotic formulation containing Lactobacillus Paracasei B 20160
Trial: 17021425
Drug: 250 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ml of diluted lemon juice (G4)
Trial: 17021425
Drug: 250 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ml of whole milk (G3)
Trial: 17021425
Drug: 250 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ml of water (G2)
Trial: 10639609
Drug: Recombinant-methionyl human
RxNorm normalized name: Recombinant methionyl human bdnf
DrugBank: Recombinant methionyl brain-derived neurotrophic factor (DB16970)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant-methionyl human neurotrophin-3 (r-metHuNT3) at doses ranging from 3 to 500 microg/kg/day
Trial: 7506158
Drug: Oral nimesulide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nimesulide 300 mg/day
Trial: 7506158
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac 150 mg/day
Trial: 7506158
Drug: Rectal nimesulide
RxNorm normalized name: nimesulide Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal nimesulide 400 mg/day
Trial: 7506158
Drug: Rectal diclofenac
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diclofenac 200 mg/day
Trial: 30203153
Drug: MTX/UST combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX/UST combination therapy
Trial: 30203153
Drug: UST monotherapy
RxNorm normalized name: Ustell
DrugBank: Phenyl salicylate (DB11071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UST monotherapy
Trial: 27507876
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m2 on day 1 of every 21-day cycle) plus gefitinib (250 mg/d)
Trial: 24730621
Drug: Surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical periodontal therapy with initial scaling and root planing
Trial: 24730621
Drug: Surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical periodontal therapy without initial scaling and root planing
Trial: 22646067
Drug: Glycopyrrolate oral
RxNorm normalized name: glycopyrrolate Oral Tablet
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate oral solution
Trial: 11104295
Drug: pill placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pill placebo
Trial: 17509314
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg daily until stone clearance or for a maximum of 30 days)
Trial: 17509314
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily until stone clearance or for a maximum of 30 days)
Trial: 12352802
Drug: Two dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two dose and fractional three dose schedules of polyribosylribitol phosphate-tetanus toxoid conjugate vaccine
Trial: 12352802
Drug: Three half-doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three half-doses of polyribosylribitol phosphate-tetanus toxoid conjugate vaccine
Trial: 12352802
Drug: All dosing
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dosing regimens of polyribosylribosyl phosphate-tetanus toxoid conjugate vaccine
Trial: 9915318
Drug: Epidural alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural alfentanil (400 microg bolus + a 400‐microg/h infusion for 2 h)
Trial: 9915318
Drug: Intravenous alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alfentanil (computer-controlled infusion)
Trial: 7844365
Drug: Didanosine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine monotherapy or combination therapy with zidovudine
Trial: 28241133
Drug: Sertraline (intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (intervention in a multicentre randomised placebo-controlled trial)
Trial: 19332455
Drug: Early eptifibatide
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early eptifibatide (two boluses of 180 microg/kg administered 10 minutes apart, and a standard infusion for >= 12 hours before angiography)
Trial: 19332455
Drug: Delayed eptifibatide
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed eptifibatide (matching placebo infusion with provisional use after angiography)
Trial: 17357577
Drug: Alpha dihydroergocryptine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha dihydroergocryptine (10 mg tablets)
Trial: 11547705
Drug: Monthly educational
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly educational session (control)
Trial: 29347946
Drug: Vibrotactile sensory
RxNorm normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vibrotactile sensory augmentation during balance training
Trial: 29347946
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no sensory augmentation)
Trial: 25039978
Drug: Esomeprazole or
RxNorm normalized name: esomeprazole Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole or AZD0865 (potent acid suppression treatment)
Trial: 2044903
Drug: Intravenous omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous omeprazole (40 mg)
Trial: 8513981
Drug: Intravenous omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous omeprazole (80 mg)
Trial: 22533516
Drug: Spiritual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiritual therapy intervention
Trial: 7554633
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose unfractionated heparin
Trial: 19731307
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose rituximab (375 mg/m2 x 4)
Trial: 19731307
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose rituximab (DDR)
Trial: 16706755
Drug: Cimicifuga racemosa
RxNorm normalized name: CIMICIFUGA RACEMOSA ROOT
DrugBank: Black cohosh (DB13975)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimicifuga racemosa extract (CRS) applied twice daily for 3 months
Trial: 16706755
Drug: Tissue Nutrient
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue Nutrient Solution Recovery Complex (TNS) applied twice daily for 3 months